Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06716463
Recruiting Observational

PREdicting Failure of Non-inVasIve Ventilatory Support Using Non-invaSIve mONitoring in Non-intubated Patients With Acute Hypoxemic Respiratory Failure or Post-extubation Failure. The PREVISION Study

NCT06716463 · tracked via the Priya Life Science Canada tracker
Sponsor
Unity Health Toronto
Phase
Observational
Started
2025-01-27
Last updated
2025-05-20

Condition(s) studied

Ventilatory FailureHypoxemic Respiratory FailureWeaning FailureRespiratory

Study summary

The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).

The main question, it aims to answer is:

Does abnormal regional ventilation could predict HFNC or NIV failure?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age of ≥ 18 years * Using NIV or HFNC anywhere in the hospital Exclusion Criteria: * Chronic CO2 retention * Neuromuscular disorder * Requiring home NIV (CPAP or BIPAP) * Tracheostomy * Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement

Primary outcome measure(s)

  • Difference in regional ventilation distribution (%) — The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
    The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure.

Trial sites (1)

FacilityCityRegionStatus
St. Michael's Hospital Toronto Ontario Recruiting

More Unity Health Toronto trials in Canada

Evaluating Novel Approaches That Engage and Support Vulnerable Patient Groups to Equitably Access Primary Care Starting soon
Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial Recruiting
Muscle Recruitment During Neck Flexion and Inspiratory Muscle Training Recruiting
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery Recruiting
Digital-Supported Versus Standard Consent for Advanced Therapeutic Endoscopy Starting soon

Other trials for the same condition

Identification and Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning Pathway Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06716463 on ClinicalTrials.gov ↗ ← All trials in Canada